7,12-Dimethylbenz(a)anthracene


7,12-Dimethylbenz(a)anthracene
7,12-Dimethylbenz(a)anthracene[1]
Identifiers
CAS number 57-97-6 YesY
PubChem 6001
ChemSpider 5779 YesY
ChEBI CHEBI:254496 YesY
ChEMBL CHEMBL329673 YesY
Jmol-3D images Image 1
Properties
Molecular formula C20H16
Molar mass 256.34104
Melting point

122-123 °C

Hazards
R-phrases R45 R22
S-phrases S53 S36/37 S45
Main hazards T (Toxic)
 YesY (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

7,12-Dimethylbenz(a)anthracene is an immunosuppressor and a powerful organ-specific laboratory carcinogen.[2] Also known as 7,12-dimethylbenz[α]anthracene or DMBA, this substance is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator by making necessary mutations. Tumor promotion can be induced with treatments of TPA (12-O-tetradecanoylphorbol-13-acetate) in some models of two-stage carcinogenesis.[3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.

References

  1. ^ 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
  2. ^ Miyata M, Furukawa M, Takahashi K, Gonzalez FJ, Yamazoe Y. (2001) Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ. Jpn J Pharmacol 86:302-309. Link
  3. ^ Sung YM, He G, Fischer, SM. (2005) Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development. Cancer Res 65:9304-9311

Wikimedia Foundation. 2010.

Look at other dictionaries:

  • 712-dimethylbenz[a]anthracene — 7,12 di·meth·yl·benz[a]an·thra·cene (di meth″əl benz anґthrə sēn) 9,10 dimethyl 1,2 benzanthracene; a highly carcinogenic polycyclic aromatic hydrocarbon produced during incomplete combustion of carbonaceous materials. It is… …   Medical dictionary


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.